Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis
Joint Bone Spine, Volume 82, No. 2, Year 2015
Notification
URL copied to clipboard!
Description
Previous studies showed that the control of inflammation by biological therapies has a positive effect on bone in inflammatory diseases. The objective of this study was to assess the effects on bone mineral density (BMD) and bone remodeling of an anti-IL-6 monoclonal antibody (tocilizumab (TCZ)) in patients with rheumatoid arthritis (RA). Methods: One hundred and three patients (75% women, 52 ± 12. years) with active RA were treated with TCZ 8. mg/kg + methotrexate (MTX) every 4 weeks during 48 weeks. Hip and lumbar spine BMDs were measured at baseline and after 48 weeks by dual energy X-ray absorptiometry (DXA). Pro-collagen serum type I N-terminal propeptide (PINP), serum C-terminal cross-linked telopeptide of type I collagen (CTX-I), and serum levels of total Dickkopf-1 (Dkk-1) and sclerostin were assessed at baseline, 12 and 48 weeks. Results: BMD was available for 76 patients at baseline and at the end of the study. There was no change in lumbar spine and hip BMD over 48 weeks. Serum PINP increased from baseline by 22% (P≤ 0.001) and 19% (P≤ 0.001) at week 12 and week 48, whereas serum CTX-I remained stable. Serum DKK-1 significantly decreased from baseline by -31% (P≤ 0.001) and -25% (P= 0.025) at week 12 and 48. Similar results were observed in the patients receiving low doses of oral corticosteroids. Conclusion: In this 1-year prospective open study, patients with active RA receiving TCZ and MTX had no change in BMD, a decrease in serum DKK-1 and an increase in bone formation marker. © 2014 Société française de rhumatologie.
Authors & Co-Authors
Briot, Karine
France, Paris
Hopital Cochin Ap-hp
Schaeverbeke, Thierry
France, Bordeaux
Groupe Hospitalier Pellegrin
Gaudin, Philippe
France, Grenoble
Centre Hospitalier Universitaire de Grenoble
Perdriger, Aleth
France, Rennes
Hopital Sud Chu Rennes
Vray, Muriel M.
France, Paris
Institut Pasteur, Paris
Roux, Christian Hubert
France, Paris
Hopital Cochin Ap-hp
Statistics
Citations: 53
Authors: 6
Affiliations: 7
Identifiers
Doi:
10.1016/j.jbspin.2014.10.015
ISSN:
1297319X
Research Areas
Health System And Policy
Study Design
Cohort Study
Participants Gender
Female